CD19 and precursor B-cell acute lymphoblastic leukemia: Single-cell multiplexed cytokine profiling and cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) analysis of activated CAR T infusion products show that a larger Th2 subset and increased expression of IL-4, -5, and -13 and the upstream regulator of T cell activation genes, GATA-3, were present in products from B-ALL patients who had CR for over 54 months post-infusion compared to those who had CD19+ relapse-free (RF) disease for a median of 9.6 months [94].